Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from JCR Pharmaceuticals Co., Ltd. ( (JP:4552) ) is now available.
JCR Pharmaceuticals has recognized ¥1.882 billion in government subsidy income as extraordinary income in the third quarter of FY2025, following the finalization of a subsidy related to the construction of its Kobe Science Park Center active pharmaceutical ingredient plant. The net subsidy, booked after tax-related adjustments and the exclusion of unused refundable amounts, boosts JCR’s non-recurring income for the period and underscores ongoing investment in its manufacturing infrastructure, with fuller implications for profitability and financial performance detailed in its latest nine-month earnings disclosure.
The most recent analyst rating on (JP:4552) stock is a Hold with a Yen705.00 price target. To see the full list of analyst forecasts on JCR Pharmaceuticals Co., Ltd. stock, see the JP:4552 Stock Forecast page.
More about JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty biopharmaceutical company focused on developing next-generation therapies for rare and genetic diseases, building on a 50-year legacy in Japan while expanding across the U.S., Europe and Latin America. Its portfolio in Japan includes treatments for growth disorders, MPS II (Hunter syndrome), Fabry disease, acute graft-versus-host disease and renal anemia, and it is advancing a pipeline of investigational therapies for multiple mucopolysaccharidoses and other rare conditions, underpinned by proprietary technologies and a patient-centric, innovation-driven strategy.
Average Trading Volume: 975,166
Technical Sentiment Signal: Hold
Current Market Cap: Yen83.9B
See more data about 4552 stock on TipRanks’ Stock Analysis page.